Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

p amiparib + RT/TMZ (PARP + RT/Chemo) Worldwide Worldwide PROGRAM (TARGET) COMMERCIAL RIGHTS 1 DOSE EXPANSION PIVOTAL PH1b PH2* PH2** PH3 DOSE ESC. PH1a pamiparib 1 (BGB - 290, PARP) p amiparib + TMZ (PARP + Chemo) Worldwide Solid tumors Glioblastoma ▪ Two ongoing global Ph1b/2 trials with chemotherapy: combination with radiation therapy and temozolomide (TMZ) in glioblastoma or combination with TMZ in advanced solid tumors ▪ Internal combination with tislelizumab: preliminary anti - tumor activity observed in multiple solid tumors Pamiparib Clinical Program 3L gBRCA + ovarian cancer 2L plat - sensitive ovarian cancer maintenance Solid tumor Solid tumors 46 *Some indications will not require a non - pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or 3 clinical trials. **Confi rmatory clinical trials post - approval are required for accelerated approvals. 1. Limited collaboration with Merck KGaA China Global 1L plat - sensitive gastric cancer maintenance

 


© 2016 BeiGene. All Rights Reserved.